Avista Capital Partners III GP, L.P.'s Form 4 filing
RVL Pharmaceuticals plc (RVLP) · filed Aug 9, 2022
- Accession no.
- 0001104659-22-088025
- Filed
- Aug 9, 2022, 5:18 PM ET
- Trade date
- Aug 8, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $12.4M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Avista Capital Partners III GP, L.P.CIK 0001705722 | 10% Owner |
| Orbit Co-Invest III LLCCIK 0001751056 | 10% Owner |
| Avista Healthcare Partners, L.P.CIK 0001794239 | 10% Owner |
| Avista Healthcare Partners GP, Ltd.CIK 0001799895 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 8, 2022 | Ordinary Shares | PPurchaseAcquired | +8,000,000 | $1.55 | +$12,400,000 | 23,730,864 | Direct | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.